MedPath

Vivani Medical

🇺🇸United States
Ownership
Public
Employees
44
Market Cap
$74.5M
Website
http://www.vivani.com
Introduction

Vivani Medical, Inc. is a preclinical stage biopharmaceutical company, which engages in the business of developing miniaturized, subdermal implants utilizing proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. It operates under the Biopharm Division and Neuromodulation Division segments. The company was founded by Adam Mendelsohn on May 22, 2003 and is headquartered in Alameda, CA.

Strategic Innovation in GLP-1 Obesity Treatment Justifies Buy Rating

Vivani Medical (VANI) received a Buy rating from Maxim Group's Naz Rahman, who cited the company's innovative NanoPortal drug delivery platform and potential in the GLP-1 and obesity treatment market. The Phase 1 LIBERATE-1 study in Australia aims to assess the safety and effectiveness of the NPM-115 implant, with results expected in mid-2025. H.C. Wainwright also reiterated a Buy rating with a $3.00 price target. Corporate insider sentiment is positive.
victoriaadvocate.com
·

Leading Molecular Diagnostics Company BillionToOne Announces Three Executive Appointments

BillionToOne, a molecular diagnostics company, appoints Judy Wong as VP, Controller, Alex Bisignano as VP of Business Development, and Susan Lin as VP of Information Systems to support its prenatal and oncology diagnostics business. The company has raised nearly $400 million, growing from $0 to $150 million in annual recurring revenue over five years.

Maxim Group Keeps Their Buy Rating on Neurosense Therapeutics Ltd. (NRSN)

Maxim Group's Naz Rahman maintains Buy rating on Neurosense Therapeutics Ltd. (NRSN), with shares closing at $1.13. Rahman has an average return of -13.1% and a 27.82% success rate. The analyst consensus on NRSN is a Moderate Buy with an average price target of $3.00. NRSN has a one-year high of $2.33 and a low of $0.40, with an average volume of 306.5K. Neurosense Therapeutics focuses on developing treatments for neurodegenerative diseases, with its lead candidate being PrimeC.
biospace.com
·

Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with ...

Vivani Medical's LIBERATE-1 trial, using a miniature GLP-1 (exenatide) implant, has received approval from the Bellberry Human Research Ethics Committee and the Therapeutic Goods Administration in Australia. The trial aims to assess the safety, tolerability, and pharmacokinetic profile of the implant in obese and overweight subjects, with the potential for twice-yearly administration, offering a differentiated approach to current injectable and oral treatments.

Vivani can begin first-in-human GLP-1 implant trial in Australia

Vivani Medical's subdermal GLP-1 implant trial approved in Australia; LIBERATE-1 trial to evaluate implant in obese and overweight subjects, following FDA IND approval in June. Vivani's NanoPortal technology aims for steady medication delivery over six months, targeting type 2 diabetes treatment. Trial initiation expected in Q4 2024, with data publication planned for 2025.
© Copyright 2025. All Rights Reserved by MedPath